EpiVario is developing small molecule inhibitors targeting the ACSS2 gene to modulate epigenetic processes involved in long-term memory formation and reconsolidation. This approach aims to address the distress associated with trauma memories in neuropsychiatric disorders, including PTSD and substance use disorders like nicotine addiction.
Funding
$275K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing treatments for neuropsychiatric disorders like PTSD and substance use disorders often lack efficacy because they fail to address the underlying distress associated with traumatic memories. The persistence of these distressing memories contributes to the challenges in overcoming these conditions.
Solution
EpiVario is developing neuroepigenetic modulators that target the ACSS2 enzyme to modulate memory formation and reconsolidation, offering a novel approach to treating neuropsychiatric disorders. By inhibiting ACSS2, EpiVario aims to modulate the epigenetic processes involved in long-term memory, specifically reducing the distress associated with trauma and drug-related memories. This targeted approach has the potential to improve outcomes for patients suffering from PTSD, substance use disorders, and other memory-related psychiatric conditions. The company's therapeutic strategy focuses on epigenetic gene regulation of memory formation.
Target Audience
The primary target audience includes individuals suffering from neuropsychiatric disorders such as PTSD and substance use disorders, as well as healthcare providers and researchers seeking novel therapeutic interventions for these conditions.
Features
- Proprietary small molecule inhibitors of ACSS2
- Targets epigenetic processes involved in long-term memory formation and reconsolidation
- Aims to reduce distress associated with trauma and drug-related memories
- Potential application in treating PTSD, opioid use disorder, alcohol use disorder and nicotine use disorder
- Modulates neuronal plasticity